A nationwide study in the USA has found that amyloid PET significantly influences clinical management, including the use of medications and counselling, of patients with mild cognitive impairment (MCI) or dementia. Changes in management were observed in about 60% of...
E-cigarette use disrupts normal immune response to viral infections, in women particularly
This preliminary study investigated differences in immune response between non-smokers and people who use cigarettes or e-cigarettes by inoculating 47 participants with live attenuated influenza virus (LAIV). They found that at baseline, e-cigarette use disrupted normal immune response to viral...
Pulmonary Arterial Hypertension: Early Treatment with Selexipag Most Effective
New post-hoc analyses from the large-scale GRIPHON trial assessing selexipag in patients with pulmonary arterial hypertension (PAH) demonstrate that early, aggressive treatment after diagnosis is associated with the greatest benefits, irrespective of background therapy [1]. Around a third of PAH patients currently...
First-ever effective treatment of Charcot-Marie-Tooth disease type 1a
PXT3003 is the first treatment for Charcot-Marie-Tooth disease type 1a (CMT1A) that is effective, safe, and well tolerated. This was demonstrated in the pivotal phase 3 trial PLEO-CMT. PXT3003 is a novel oral fixed-dose combination of baclofen, naltrexone, and D-sorbitol,...